Jefferson Digital

No abstract is available for this paper.

• Publication year

  2022

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes

  2011cited by this paper
• Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects

  2010cited by this paper
• Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.

  2008cited by this paper
• Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

  2007influential reference
• Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

  2007influential reference
• Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

  2007influential reference
• The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.

  2006cited by this paper
• Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

  2006cited by this paper
• Langerhans cells release prostaglandin D2 in response to nicotinic acid.

  2006cited by this paper
• Nicotinic Acid-Induced Flushing Is Mediated by Activation of Epidermal Langerhans Cells

  2006cited by this paper
• Nicotinic acid: the broad‐spectrum lipid drug. A 50th anniversary review

  2005cited by this paper
• Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.

  2004cited by this paper
• Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance

  2004cited by this paper
• The P2Y1 receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented

  2004cited by this paper
• The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

  2001cited by this paper
• Niacin dosing: Relationship to benefits and adverse effects

  2000cited by this paper
• A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.

  1998cited by this paper
• Clopidogrel: a review of its mechanism of action.

  1998cited by this paper
• Aspirin as an antiplatelet drug.

  1994cited by this paper
• Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.

  1992cited by this paper
• Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders.

  1991cited by this paper
• Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid.

  1989cited by this paper
• Prostaglandins and nicotinate‐provoked increase in cutaneous blood flow

  1985cited by this paper
• Is cutaneous flushing prostaglandin mediated?

  1981cited by this paper
• The bleeding time as a screening test for evaluation of platelet function.

  1972cited by this paper

• No citing papers are available for this paper.